Cargando…

ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma

BACKGROUND: Sustained activation of hepatocyte growth factor (HGF)/c-MET signaling is a major driver of hepatocellular carcinoma (HCC) progression, but underlying mechanism is unclear. ArfGAP With SH3 Domain, Ankyrin Repeat And PH Domain 2 (ASAP2) can reportedly activate GTPases and promote receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiao-Lu, Nie, Yan-Yan, Xie, Su-Hong, Zheng, Hui, Tong, Ying, Wang, Yan-Chun, Yan, Tian-Qing, Meng, Xin, Cao, Jia-Zhen, Tang, Wei-Guo, Guo, Lin, Lu, Ren-Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105420/
https://www.ncbi.nlm.nih.gov/pubmed/37061723
http://dx.doi.org/10.1186/s40164-023-00393-3
_version_ 1785026207307268096
author Ma, Xiao-Lu
Nie, Yan-Yan
Xie, Su-Hong
Zheng, Hui
Tong, Ying
Wang, Yan-Chun
Yan, Tian-Qing
Meng, Xin
Cao, Jia-Zhen
Tang, Wei-Guo
Guo, Lin
Lu, Ren-Quan
author_facet Ma, Xiao-Lu
Nie, Yan-Yan
Xie, Su-Hong
Zheng, Hui
Tong, Ying
Wang, Yan-Chun
Yan, Tian-Qing
Meng, Xin
Cao, Jia-Zhen
Tang, Wei-Guo
Guo, Lin
Lu, Ren-Quan
author_sort Ma, Xiao-Lu
collection PubMed
description BACKGROUND: Sustained activation of hepatocyte growth factor (HGF)/c-MET signaling is a major driver of hepatocellular carcinoma (HCC) progression, but underlying mechanism is unclear. ArfGAP With SH3 Domain, Ankyrin Repeat And PH Domain 2 (ASAP2) can reportedly activate GTPases and promote receptor tyrosine kinase signaling. However, the exact role of ASAP2 in HCC, especially for c-MET activation, also remains elusive. METHODS: ASAP2 expression levels in HCC tissues and cells were quantified using qRT-PCR, western blot (WB) analysis, and immunohistochemistry staining. Cell counting kit-8 (CCK-8) and colony formation assays were performed to evaluate cell proliferation rates. Flow cytometry assays were conducted to assess apoptosis rates. Wound healing and Transwell assays were performed to determine cell migration and invasion capacities. Epithelial-mesenchymal transition (EMT)-related marker expression levels were also examined. Subcutaneous implantation and tail vein injection models were applied for in vivo growth and metastasis evaluations, respectively. Bioinformatics analyses of The Cancer Genome Atlas and STRING datasets were performed to explore ASAP2 downstream signaling. Co-immunoprecipitation and Cycloheximide chasing experiments were performed to assess protein–protein interactions and protein half-life, respectively. RESULTS: ASAP2 had higher expression levels in HCC tissues than in normal liver, and also predicted poor prognosis. Knocking down ASAP2 significantly impaired cell proliferation, migration, and invasion capacities, but promoted apoptosis in HCC cells in vitro. However, overexpression of ASAP2 achieved the opposite effects. In vivo experiments confirmed that ASAP2 could promote HCC cell growth and facilitate lung metastasis. Interestingly, ASAP2 was essential for triggering EMT. Gene Set Enrichment Analysis demonstrated that c-MET signaling was greatly enriched in ASAP2-high HCC cases. Additionally, c-MET signaling activity was significantly decreased following ASAP knockdown, evidenced by reduced c-MET, p-AKT, and p-ERK1/2 protein levels. Importantly, ASAP2 knockdown effectively attenuated HGF/c-MET signaling-induced malignant phenotypes. c-MET and ASAP2 expression levels were positively correlated in our cohort. Mechanistically, ASAP2 can directly bind to CIN85, thereby disrupting its interaction with c-MET, and can thus antagonize CIN85-induced c-MET internalization and lysosome-mediated degradation. Notably, knocking down CIN85 can rescue the observed inhibitory effects caused by ASAP2 knockdown. CONCLUSIONS: This study highlights the importance of ASAP2 in sustaining c-MET signaling, which can facilitate HCC progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-023-00393-3.
format Online
Article
Text
id pubmed-10105420
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101054202023-04-16 ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma Ma, Xiao-Lu Nie, Yan-Yan Xie, Su-Hong Zheng, Hui Tong, Ying Wang, Yan-Chun Yan, Tian-Qing Meng, Xin Cao, Jia-Zhen Tang, Wei-Guo Guo, Lin Lu, Ren-Quan Exp Hematol Oncol Research BACKGROUND: Sustained activation of hepatocyte growth factor (HGF)/c-MET signaling is a major driver of hepatocellular carcinoma (HCC) progression, but underlying mechanism is unclear. ArfGAP With SH3 Domain, Ankyrin Repeat And PH Domain 2 (ASAP2) can reportedly activate GTPases and promote receptor tyrosine kinase signaling. However, the exact role of ASAP2 in HCC, especially for c-MET activation, also remains elusive. METHODS: ASAP2 expression levels in HCC tissues and cells were quantified using qRT-PCR, western blot (WB) analysis, and immunohistochemistry staining. Cell counting kit-8 (CCK-8) and colony formation assays were performed to evaluate cell proliferation rates. Flow cytometry assays were conducted to assess apoptosis rates. Wound healing and Transwell assays were performed to determine cell migration and invasion capacities. Epithelial-mesenchymal transition (EMT)-related marker expression levels were also examined. Subcutaneous implantation and tail vein injection models were applied for in vivo growth and metastasis evaluations, respectively. Bioinformatics analyses of The Cancer Genome Atlas and STRING datasets were performed to explore ASAP2 downstream signaling. Co-immunoprecipitation and Cycloheximide chasing experiments were performed to assess protein–protein interactions and protein half-life, respectively. RESULTS: ASAP2 had higher expression levels in HCC tissues than in normal liver, and also predicted poor prognosis. Knocking down ASAP2 significantly impaired cell proliferation, migration, and invasion capacities, but promoted apoptosis in HCC cells in vitro. However, overexpression of ASAP2 achieved the opposite effects. In vivo experiments confirmed that ASAP2 could promote HCC cell growth and facilitate lung metastasis. Interestingly, ASAP2 was essential for triggering EMT. Gene Set Enrichment Analysis demonstrated that c-MET signaling was greatly enriched in ASAP2-high HCC cases. Additionally, c-MET signaling activity was significantly decreased following ASAP knockdown, evidenced by reduced c-MET, p-AKT, and p-ERK1/2 protein levels. Importantly, ASAP2 knockdown effectively attenuated HGF/c-MET signaling-induced malignant phenotypes. c-MET and ASAP2 expression levels were positively correlated in our cohort. Mechanistically, ASAP2 can directly bind to CIN85, thereby disrupting its interaction with c-MET, and can thus antagonize CIN85-induced c-MET internalization and lysosome-mediated degradation. Notably, knocking down CIN85 can rescue the observed inhibitory effects caused by ASAP2 knockdown. CONCLUSIONS: This study highlights the importance of ASAP2 in sustaining c-MET signaling, which can facilitate HCC progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-023-00393-3. BioMed Central 2023-04-15 /pmc/articles/PMC10105420/ /pubmed/37061723 http://dx.doi.org/10.1186/s40164-023-00393-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ma, Xiao-Lu
Nie, Yan-Yan
Xie, Su-Hong
Zheng, Hui
Tong, Ying
Wang, Yan-Chun
Yan, Tian-Qing
Meng, Xin
Cao, Jia-Zhen
Tang, Wei-Guo
Guo, Lin
Lu, Ren-Quan
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
title ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
title_full ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
title_fullStr ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
title_full_unstemmed ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
title_short ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
title_sort asap2 interrupts c-met-cin85 interaction to sustain hgf/c-met-induced malignant potentials in hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105420/
https://www.ncbi.nlm.nih.gov/pubmed/37061723
http://dx.doi.org/10.1186/s40164-023-00393-3
work_keys_str_mv AT maxiaolu asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT nieyanyan asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT xiesuhong asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT zhenghui asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT tongying asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT wangyanchun asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT yantianqing asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT mengxin asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT caojiazhen asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT tangweiguo asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT guolin asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma
AT lurenquan asap2interruptscmetcin85interactiontosustainhgfcmetinducedmalignantpotentialsinhepatocellularcarcinoma